CMS Grants Category B Coverage for Adults with Acute Kidney Injury Enrolled in SeaStar Medical’s Selective Cytopheretic Device Pivotal Trial
16 juil. 2024 08h30 HE
|
SeaStar Medical Holding Corporation
Reimbursement expected to accelerate medical site activations and cover a portion of the Company’s NEUTRALIZE-AKI trial costs DENVER, July 16, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding...
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages SeaStar Medical Holding Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – ICU
14 juil. 2024 15h04 HE
|
The Rosen Law Firm PA
NEW YORK, July 14, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of SeaStar...
SeaStar Medical Ships First QUELIMMUNE Product Order to U.S. Distribution Partner
12 juil. 2024 08h30 HE
|
SeaStar Medical Holding Corporation
DENVER, July 12, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) reports the initial commercial sale of QUELIMMUNE™-Pediatric to its U.S. license and...
SeaStar Medical Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
11 juil. 2024 16h05 HE
|
SeaStar Medical Holding Corporation
DENVER, July 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) announces that it has closed its previously announced registered offering for the...
SeaStar Medical Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
10 juil. 2024 09h00 HE
|
SeaStar Medical Holding Corporation
DENVER, July 10, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical), today announced it has entered into a definitive agreement for the issuance and sale of...
SeaStar Medical Strengthens Board of Directors and Transitions to Commercial-Stage Company
10 juin 2024 08h30 HE
|
SeaStar Medical Holding Corporation
DENVER, June 10, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) announces that three new members have joined its Board of Directors. Two new directors,...
Article in Nature Scientific Reports Describes Mechanism of Action of SeaStar Medical’s Selective Cytopheretic Device in the Immunomodulation of Excessive Inflammation
07 juin 2024 08h30 HE
|
SeaStar Medical Holding Corporation
DENVER, June 07, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
SeaStar Medical to Present at the Virtual Emerging Growth Conference on June 12, 2024
06 juin 2024 16h05 HE
|
SeaStar Medical Holding Corporation
DENVER, June 06, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of...
SeaStar Medical Announces 25-for-1 Reverse Stock Split
06 juin 2024 08h30 HE
|
SeaStar Medical Holding Corporation
DENVER, June 06, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation...
Manuscript Published on Multiorgan Failure Patients Treated with SeaStar Medical’s Selective Cytopheretic Device Who Achieved Transplant Eligibility
22 mai 2024 08h30 HE
|
SeaStar Medical Holding Corporation
SCD’s ability to improve clinical status of four critically ill pediatric and adult patients across multiple clinical conditions published in Transplantation Direct DENVER, May 22, 2024 (GLOBE...